Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Avidity-Controlled Delivery of Angiogenic Peptides from Injectable Molecular-Recognition Hydrogels
2014
Targeted therapies for breast cancer
2011
Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
2014
Pharmacologic Targeting of Hypoxia-Inducible Factors
2019 StandoutNobel
Feasibility and Cardiac Safety of Trastuzumab Emtansine After Anthracycline-Based Chemotherapy As (neo)Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2–Positive Early-Stage Breast Cancer
2015
Breast cancer
2019 Standout
Lapatinib and breast cancer: current indications and outlook for the future
2010
A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine
2012
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge
2017 StandoutNobel
Intracellular Delivery System for Antibody–Peptide Drug Conjugates
2015 StandoutNobel
Lapatinib and 17AAG Reduce 89Zr-Trastuzumab-F(ab′)2 Uptake in SKBR3 Tumor Xenografts
2012
New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs Available
2011
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
2016
Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO)
2007
LC–MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1)
2017
A view on drug resistance in cancer
2019 StandoutNature
Lipid nanoparticles for mRNA delivery
2021 Standout
mRNA-based therapeutics — developing a new class of drugs
2014 StandoutNobel
Vascular Endothelial Growth Factor-Delivery Systems for Cardiac Repair: An Overview
2012
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics
2013
Linker Technologies for Antibody–Drug Conjugates
2013
Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates
2015
Pharmacokinetic aspects of biotechnology products
2004
Immunoconjugates and long circulating systems: Origins, current state of the art and future directions
2012
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
2011 Standout
Controlled delivery of VEGF via modulation of alginate microparticle ionic crosslinking
2008
CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
2019 StandoutNobel
Antibody drug conjugates
2014
Cancer stem cells revisited
2017 Standout
Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology
2006 StandoutNobel
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
2007
Nano based drug delivery systems: recent developments and future prospects
2018 Standout
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
2012
Dissecting muscle and neuronal disorders in a Drosophila model of muscular dystrophy
2007 StandoutNobel
Rapid online buffer exchange for screening of proteins, protein complexes and cell lysates by native mass spectrometry
2020 StandoutNobel
Non-viral vectors for gene-based therapy
2014 Standout
Site-specific antibody drug conjugates for cancer therapy
2013
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
2015 Standout
Alginate: Properties and biomedical applications
2011 Standout
Immunoconjugates Against Solid Tumors: Mind the Gap
2011
Targeting apoptosis in cancer therapy
2020 Standout
State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines
2014
8thAnnual European Antibody Congress 2012
2013
Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis
2007
Designing hydrogels for controlled drug delivery
2016 Standout
High-Resolution Microtubule Structures Reveal the Structural Transitions in αβ-Tubulin upon GTP Hydrolysis
2014 StandoutNobel
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo
2012 Standout
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Adverse effects of anticancer agents that target the VEGF pathway
2009
The von Hippel–Lindau protein, HIF hydroxylation, and oxygen sensing
2005 StandoutNobel
Mesoporous Materials for Drug Delivery
2007 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction
2013
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
2017 Standout
New developments for antibody-drug conjugate-based therapeutic approaches
2016
Lysosome-targeting chimaeras for degradation of extracellular proteins
2020 StandoutNatureNobel
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
2010
Evaluation of HIF-1 inhibitors as anticancer agents
2007 StandoutNobel
Tumor Angiogenesis
2008 Standout
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
2019
Wound repair and regeneration: Mechanisms, signaling, and translation
2014 Standout
Supramolecular biomaterials
2015 Standout
Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy
2023 StandoutNobel
Cu and Cu-Based Nanoparticles: Synthesis and Applications in Catalysis
2016 Standout
The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer
2004 StandoutNobel
Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α
2004
Systemic delivery of genes to striated muscles using adeno-associated viral vectors
2004
Regulation of Apoptosis by HER2 in Breast Cancer
2013
Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
2010
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
2012 Standout
Ionizable lipid nanoparticles deliver mRNA to pancreatic β cells via macrophage-mediated gene transfer
2023 StandoutNobel
Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine‐linked antibody drug conjugate
2015
Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation
2016
Nanomedicine(s) under the Microscope
2011
A Pictet-Spengler ligation for protein chemical modification
2012 StandoutNobel
Heterocyclic Anticancer Compounds: Recent Advances and the Paradigm Shift towards the Use of Nanomedicine’s Tool Box
2015 Standout
Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers
2008
Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha.
2004
Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development
2014 StandoutNobel
Emerging Targets in Photopharmacology
2016 StandoutNobel
Analysis of nanoparticle delivery to tumours
2016 Standout
Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
2013
Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody–Drug Conjugates
2015
Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles
2004 StandoutNobel
Regulation of angiogenesis by hypoxia-inducible factor 1
2006 StandoutNobel
Works of Joo‐Hee Yi being referenced
An Integrated Multiple-Analyte Pharmacokinetic Model to Characterize Trastuzumab Emtansine (T-DM1) Clearance Pathways and to Evaluate Reduced Pharmacokinetic Sampling in Patients with HER2-Positive Metastatic Breast Cancer
2013
Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
2010
Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
2012
Immunogenicity Assays for Antibody–Drug Conjugates: Case Study with Ado-Trastuzumab Emtansine
2013
A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans
2002
Effects of Trastuzumab Emtansine (T‐DM1) on QT Interval and Safety of Pertuzumab Plus T‐DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
2013
PK Assays for Antibody–Drug Conjugates: Case Study with Ado-Trastuzumab Emtansine
2013